KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Accumulated Depreciation (2016 - 2018)

Historic Accumulated Depreciation for Arbutus Biopharma (ABUS) over the last 9 years, with Q4 2018 value amounting to $6.9 million.

  • Arbutus Biopharma's Accumulated Depreciation fell 4557.65% to $6.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $6.9 million, marking a year-over-year decrease of 4557.65%. This contributed to the annual value of $6.9 million for FY2018, which is 4557.65% down from last year.
  • As of Q4 2018, Arbutus Biopharma's Accumulated Depreciation stood at $6.9 million, which was down 4557.65% from $6.4 million recorded in Q3 2018.
  • Arbutus Biopharma's Accumulated Depreciation's 5-year high stood at $13.3 million during Q1 2018, with a 5-year trough of -$10.1 million in Q1 2015.
  • Moreover, its 5-year median value for Accumulated Depreciation was $10.6 million (2016), whereas its average is $9.4 million.
  • Per our database at Business Quant, Arbutus Biopharma's Accumulated Depreciation skyrocketed by 20065.5% in 2014 and then crashed by 18565.76% in 2015.
  • Over the past 5 years, Arbutus Biopharma's Accumulated Depreciation (Quarter) stood at $11.2 million in 2014, then decreased by 13.13% to $9.7 million in 2015, then rose by 10.37% to $10.7 million in 2016, then increased by 18.0% to $12.7 million in 2017, then tumbled by 45.58% to $6.9 million in 2018.
  • Its last three reported values are $6.9 million in Q4 2018, $6.4 million for Q3 2018, and $5.9 million during Q2 2018.